Vaccination using plant virus particles linked to her2 antigens

2-4. (canceled)

5:

• The vaccine composition of claim 1, wherein the HER2 antigen comprises a B-cell epitope from the extracellular domain of HER2.

6:

• The vaccine composition of claim 1, wherein the HER2 antigen comprises SEQ ID NO:
• 1.

7:

• The vaccine composition of claim 1, further comprising a pharmaceutically acceptable carrier.

8:

• The vaccine composition of claim 1, further comprising an adjuvant.

9:

• A method of treating or decreasing the risk of developing an HER2-expressing cancer in a subject, by administering to a subject in need thereof an effective amount of a vaccine composition comprising a potato virus X particle linked to an HER2 antigen.

10:

• The method of claim 9, wherein the HER2-expressing cancer is breast cancer.

11-13. (canceled)

14:

• The method of claim 9, wherein the HER2 antigen comprises a B-cell epitope from the extracellular domain of HER2

15:

• The method of claim 9, wherein the HER2 antigen comprises SEQ ID NO:
• 1.

16:

• The method of claim 9, wherein the composition further comprises a pharmaceutically acceptable carrier.

17:

• The method of claim 9, wherein the composition further comprises an adjuvant.

18:

• The method of claim 9, wherein the vaccine composition is administered parenterally.

19:

• The method of claim 9, wherein the vaccine composition is administered orally.

(canceled)

21:

• The vaccine composition of claim 1, wherein the HER2 antigen comprises a cysteine terminated P4 peptide with an intervening flexible linker.

22:

• The vaccine composition of claim 21, wherein the flexible linker is a polyglycine linker.

23:

• The method of claim 9, wherein the HER2 antigen comprises a cysteine terminated P4 peptide with an intervening flexible linker.

24:

• The method of claim 23, wherein the flexible linker is a polyglycine linker.